Any treatment would reach those who can pay long before anyone else

The argument

Opponents argue that the distribution of the result matters as much as the result. New medical treatments are expensive when they arrive, are available first through private medicine and in wealthy countries, and reach everyone else slowly or not at all. Applied to ageing, opponents argue, this pattern would operate on the one good that has so far been distributed with rough equality: the length of a human life. Differences in lifespan already follow income, but nobody has yet been able to purchase extra decades outright. The objection is that such a treatment would convert existing advantage into biological advantage, and then compound it. Those who could buy additional healthy years would accumulate earnings, property, seniority and political influence over a longer span than everyone else, while those who could not would watch a longer life become another thing available to the rich. Opponents argue this is different in kind from unequal access to a cancer drug, because the benefit is general rather than specific to an illness, and because its holders would use the time to entrench the position that allowed them to buy it. Opponents also argue that public money would be doing the work of that outcome. Basic research is paid for collectively and the resulting treatments are commonly sold back at prices that collective provision cannot meet, so the public would be funding the development of a benefit it would then be excluded from. On this account the question is not whether slowing ageing would be good for an individual who received it, but whether a society should direct scarce research funding towards a good it has no mechanism to share, and opponents hold that it should not.

Premises

Counter-arguments

Supporters reply that this argument would block almost all medical research, since every treatment is costly and unequally distributed at first and then becomes cheap and widespread, which is the history of vaccines, antibiotics and surgery alike. They argue that the remedy for unequal access is public purchasing, patent conditions and manufacturing at scale, all of which are policy choices rather than reasons to leave the science undone. They also note that the poorest suffer most from age-related disease, since they reach frailty earlier and with less care available, so refusing the research withholds the largest potential gain from exactly the people the objection is concerned about.

Rejecting the premises

[Rejecting P1] The same was true of vaccines, antibiotics and surgery, each of which became cheap and widespread, so initial inequality of access is a stage rather than an endpoint. [Rejecting P2] The compounding described depends on the treatment remaining exclusive, which is a policy outcome that public purchasing, patent conditions and manufacturing at scale can prevent. [Rejecting P3] That publicly funded research yields privately priced products is an argument for attaching conditions to public funding, not for declining to fund the science. [Rejecting C] Refusing the research withholds the largest potential gain from the poorest, who reach frailty earlier and with less care available.